anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to preparation technology and a production method of a ginger decoction-integrated new formulation. The ginger decoction-integrated new formulation comprises the following raw materials by weight: 2 parts of dry ginger, 13 parts of liquorice, 10 parts of almond, 3 parts of fried flour and 22 parts of fried salts. The production process comprises the steps of supersonic air flow pulverization, alcohol and water extraction, ultrasonic pulverization and extraction, water decoction and concentration, supersonic spray drying, nanogrinding, high-pressure homogenization, nanoparticle preparation and the like. The invention emphasize the advantages of multi-collaboration, multi-targeting and the like presented by adopting a nanocarrier coupling technique. After large-scale production, the production cost can be greatly reduced, product quality can be greatly improved, and the targeting and the slow and controlled release of the medicine can be stronger. The ginger decoction-integrated new formulation can be together administered orally or topically and respectively taken by midnight-midday ebb flows and the Qi and blood flowing rules of human bodies at four periods of time. The ginger decoction-integrated new formulation can also be prepared into a film-forming agent and a transdermal agent which are respectively attached in different positions of the human bodies by the midnight-midday ebb flows and the qi and blood flowing rules of the human bodies and can be directly absorbed by skin.
The present invention belongs to the technical field of health-care medicated spirit, which discloses the health-care medicated spirit with certain therapeutic effects on high blood pressure and angina pectoris. The present invention is mainly characterized in that glutinous millet is infused and braized and is taken out for cooling; the glutinous millet is stirred by adding grain distilled spirit; the glutinous millet is saccharified and fermented and is added to Chinese herbal medicine such as notoginseng, ginseng, lucid ganoderma, matrimony vine, red sage root, safflower, schisandra fruit, apricot kernel, astragalus root, chuanxiong rhizome, kudzuvine root, etc.; the glutinous millet and the Chinese herbal medicine are infused and squeezed by grain Chinese spirit with high alcohol content or by mineralized water for forming medicinal liquid; the medicinal liquid is secondarily fermented and squeezed for forming liquid as crude spirit; the obtained crude spirit is heated, ripened and disinfected, and the health-care medicated spirit is produced. The medicated spirit uses glutinous millet as basal materials and is formed by fermenting and brewing by adding medicinal liquid. The present invention has the characteristics of low alcohol content and wide drinking people. The health-care medicated spirit has excellent effects on high blood pressure and angina pectoris.
PROBLEM TO BE SOLVED: To obtain a hair cosmetic preparation enabling damaged hair to keep moisture, and having good split hair-restoring and luster-giving effects, by compounding a keratose and a complex of an ampholytic surfactant, etc., with a higher fatty acid. SOLUTION: This hair cosmetic preparation contains (A) a keratose which is cationized with a quaternary ammonium salt and (B) a complex of an ampholytic surfactant and/or a semipolar surfactant with a higher fatty acid. The keratose is obtained by hydrolyzing keratin, and preferably has an average molecular weight of 5,500-35,200. A cationization agent for cationizing the component A is a quaternary ammonium compound of formula I (R1 is a lower alkyl; R2 is a 1-20C alkyl or the like; R3 is a 1-24C alkylene or the like; X is a halogen; Y is a reactive group). The component A is preferably contained in an amount of 0.1-2.0 wt.% based on the total amount of the preparation. An amidobetaine type ampholytic surfactant of formula II is exemplified as the component B.
Aqueous emulsions or dispersions suitable for use as contact liquids in producing electrocardiograms or electroencephalograms comprise a water-insoluble surface active agent as dispersed phase, a water-soluble surface active agent as dispersing agent and a highly ionizable alkali metal salt in solution, the emulsion or dispersion being buffered to a pH of 4-8.  Specified waterinsoluble surface active agents are polyoxyalkylene derivatives of fatty acids having from 12-18 carbon atoms, fatty acid esters of sorbitol anhydrides (sorbitan monolaurate, monopalmitate and monooleate), glyceryl monostearate and methylene bis-stearamide which may form 10-11% of the composition. Specified watersoluble surface active agents are polyoxyalkylene sorbitan monolaurate, monopalmitate and monooleate, stearyl polyoxyethylamine and sodium lauryl sulphate which may form 1,6-1,7% of the composition.  In an example a blend of ethylene oxide derivatives of lanolin-higher fatty alcohols is used as a mixture of water-soluble and waterinsoluble surface active agent.  Specified salts are sodium chloride, potassium chloride and sodium sulphate which may be present in a concentration of 1-10% by weight.  In addition to the buffer (e.g. sodium phosphate/sodium acid phosphate or sodium citrate/citric acid), bacteria-, mould- or yeast-inhibitors such as esters of p-hydroxybenzoic acid, and preservatives e.g. acetic acid, glyceryl or cetyl alcohol, may be used.  In the examples sodium nitrite is also present and the compositions are pressurized with nitrogen.ALSO:Aqueous emulsions or dispersions suitable for use as contact liquids in producing electrocardiograms or electroencephalograms comprise a water-insoluble surface active agent as dispersed phase, a water-soluble surface active agent as dispersing agent and a highly ionisable alkali metal salt in solution, the emulsion or dispersion being buffered to a pH of 4-8. Specified water-insoluble surface active agents are polyoxyalkylene derivatives of fatty acids having from 12-18 carbon atoms, fatty acid esters of sorbitol anhydrides (sorbitan monolaurate, monopalmitate and mono-oleate), glyceryl monostearate and methylene bis-stearamide which may form 10-11% of the composition.  Specified water-soluble surface active agents are polyoxyalkylene sorbitan monolaurate, monopalmitate and mono-oleate, stearyl polyoxyethylamine and sodium lauryl sulphate which may form 1.6-1.7% of the composition.  In an example a blend of ethylene oxide derivatives of lanolin-higher fatty alcohols is used as a mixture of water-soluble and water-insoluble surface active agent.  Specified salts are sodium chloride, potassium chloride and sodium sulphate which may be present in a concentration of 1-10% by weight.  In addition to the buffer (e.g. sodium phosphate/sodium acid phosphate or sodium citrate/citric acid), bacteria-, mould- or yeast-inhibitors, such as esters of p-hydroxybenzoic acid, and preservatives, e.g. acetic acid, glycerol or cetyl alcohol, may be used.  In the examples sodium nitrite is also present and the compositions are pressurized with nitrogen.
An information processing apparatus according includes processing circuitry. The processing circuitry adds a correct answer label used for training a decision making model, which is used for decision making in a medical care field, in accordance with an operator's input instruction. The processing circuitry collects status data indicating an operator's status while doing the work of adding a correct answer label. The processing circuitry trains a reliability level determination model which accepts status data and outputs a reliability level of a correct answer label. The processing circuitry obtains input data of a decision making model. The processing circuitry trains a decision making model which accepts input data and outputs output data indicating a result of decision making.
This is a two-group controlled study to test the following hypothesis: compared to body mass index (BMI)-matched normal controls, women with polycystic ovary syndrome (PCOS) will demonstrate blunted LH responses to preovulatory estradiol concentrations. We will study both normally-cycling controls and women with PCOS. We aim to recruit BMI-matched pairs (PCOS vs. control within 2 kg/m2). To provoke a gonadotropin surge, subjects will receive graded transdermal estradiol dosing, and we will use a dose adjustment protocol to maintain serum estradiol levels of 250-400 pg/ml. To enhance reliability of estradiol delivery, transdermal estradiol patches will be placed/replaced daily by Clinical Research Unit (CRU) nurses, and abdominal sites will be rotated. All subjects will begin estradiol on menstrual cycle day 4. Starting 24 hours before E2 administration, all subjects will collect all urine output in 12-hour time blocks for later urinary LH and FSH analysis; this will continue until the end of the study. Additionally, subjects will have daily morning blood draws in the CRU for later hormone measurements. Transvaginal ovarian ultrasound will be performed on study day 6 -- near the time of expected surge initiation -- to document largest follicle sizes. We will measure serum estradiol daily and employ an estradiol dose-adjustment protocol to maintain target estradiol levels. We will also measure LH daily. The study will be stopped after either (a) serum LH increases to 5-fold higher than baseline and subsequently falls to within 200% of baseline, or (b) the subject has received estradiol for a full 7 days, whichever comes first. The primary endpoint will be estradiol-induced change in 24-hour urinary LH excretion, defined as 24-hour mean values immediately prior to estradiol administration vs. peak 24-hour mean values during estradiol administration. A comparison of 24-hour LH changes between healthy normal and PCOS groups will be conducted by way of a random-effects analysis of covariance (ANCOVA) model. The ANCOVA model will be specified so that each BMI-matched pair will represent an independent observational unit with respect to comparing 24-hour LH change between groups. With regard to hypothesis testing, we will test whether the component of variability in 24-hour LH change attributed to "Study Group" (healthy normal control vs. PCOS) is a significant component of the overall variability in 24-hour LH change. Variability in 24-hour LH change attributed to baseline disparities in LH will be accounted for by treating subject-specific baseline LH as a covariate in the ANCOVA model. If BMI matching is inadequate, we will also include BMI as a covariate in the model. If 11 women with PCOS and 11 controls complete study, we expect at least 80% power to detect a 33% difference in E2-induced augmentation of urinary LH excretion.
BACKGROUND AND PURPOSE: Uncemented stems increase the risk of revision in elderly patients. In 2018, we initiated a national quality improvement project aiming to increase the proportion of cemented stems in elderly female total hip arthroplasty (THA) and hip fracture hemiarthroplasty (HA) patients. We aimed to evaluate the association of this project on the frequency of cemented stems and the risk of secondary procedures in the targeted population.
METHODS: 10,815 THAs in female patients ≥ 75 years in the Norwegian Arthroplasty Register and 19,017 HAs in hip fracture patients ≥ 70 years in the Norwegian Hip Fracture Register performed in 2015-2017 and 2019-2021 at all Norwegian hospitals were included in this retrospective cohort study. The quality improvement project was implemented at 19 hospitals (8,443 patients). 1-year revision risk (THAs) and reoperation risk (HAs) were calculated for uncemented and cemented stems by Kaplan-Meier and Cox adjusted hazard rate ratios (aHRRs) with all-cause revision/reoperation as main endpoint.
RESULTS: The use of cemented stem fixation in the targeted population increased from 26% to 80% for THAs and from 27% to 91% for HAs. For THAs, the 1-year revision rate decreased from 3.7% in 2015-2017 to 2.1% in 2019-2021 (aHRR 0.7, 95% confidence interval [CI] 0.5-0.9) at the intervention hospitals. For HAs, the reoperation rate decreased from 5.9% in 2015-2017 to 3.3% in 2019-2021 (aHRR 0.6, CI 0.4-0.8) at the intervention hospitals.
CONCLUSION: The quality improvement project resulted in a significant increase in the proportion of cemented stems and reduced risk of secondary procedures for both THAs and HAs.
Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular disease (CVD). African Americans have higher rates of LVH and CVD than whites. Substantial evidence indicates that psychological stress contributes to LVH. This randomized controlled trial evaluated the effect of stress reduction with the Transcendental Meditation (TM) technique on left ventricular mass (LVM) in hypertensive African-Americans.

Hypertensive African American men and women were tested at baseline for left ventricular mass index (LVMI) by M-mode echocardiography, blood pressure, lifestyle and behavioral factors. Subjects were randomly assigned to either TM or health education (HE) control. After six months intervention, 86 subjects were posttested on all outcomes. Data were analyzed for between-group and within-group differences.
In each participant, HRV will be measured for 2 minutes, then the flying buttress technique will be applied. After the technique, HRV will be recorded for 2 minutes, and 5 minutes later, HRV will be measured again for 2 minutes.
The present invention relates to a recipe for protecting pancreas functions, regulating a whole human body for regulating the blood sugar of the human body and a production method, which belongs to the technical field of health foods. At present, no acute and chronic toxic or side effects exist for eating for a long period by the experimental verification of scientific research departments of the medical board of the peking university, a city disease control center and the west traditional Chinese medical hospital of an academy of traditional Chinese medicine. By animal and human body tests, the present invention has obvious functions of health care and auxiliary blood sugar regulation and is already submitted to a health ministry for an approval. The recipe is prepared according to proportion that rhizome: ophiopogon root: anemarrhenae: wofberry bark: jiaogulan is equal to 2: 2: 2: 2: 1. Pancreas protecting and health preserving effects of Chinese herbal medicine are operated to the health foods. The pure Chinese herbal medicine health foods of preventing diabetes and has no toxic or side effects. The product of the present invention has the advantages of fragrant odor and comfortable mouth feeling and is suitable for the health foods which are frequently eaten for preventing the diabetes.
PROBLEM TO BE SOLVED: To provide a nonmagnetic one-component developer with excellent durability in which the surface state of the toner is hardly changed and toner characteristics can be maintained even when the developer is used for repeated copying. SOLUTION: This nonmagnetic one-component developer contains toner particles having 4 to 10 μm volume average particle size (D) containing at least a binder resin and a coloring agent, first inorg. fine particles having 1 to 40 nm primary average particle size, second inorg. fine particles having 40 to 100 average primary particle size larger by >=10 nm than that of the first inorg. fine particles, and third inorg. fine particles having 100 nm to 1000D/16 nm average primary particle size and larger by >=10 nm than that of the second inorg. fine particles. The proportion of the first and second inorg. fine particles are controlled to 0.1 to 2 wt.% and 0.1 to 2.5 wt.%, respectively of the toner particles, with 0.8 to 3 wt.% of the sum to the toner particles. The proportion of the third inorg. fine particles is 0.3 to 3 wt.% of the toner particles.
There have been no reports of overdose with CRYSVITA. CRYSVITA has been administered in pediatric clinical trials without dose limiting toxicity using doses up to 2 mg/kg body weight with a maximal dose of 90 mg, administered every two weeks. In XLH adult clinical trials, no dose limiting toxicity has been observed using doses up to 1 mg/kg or a maximal total dose of 128 mg every 4 weeks. In non-XLH rabbits and cynomolgus monkeys, ectopic mineralization in multiple tissues and organs was observed at doses of burosumab-twza that resulted in supra-physiologic serum phosphate levels. Adverse effects on bone including reductions in bone mineral density, bone mineralization and bone strength were also observed at exposure greater than human exposure [see Nonclinical Toxicology (13.2)].

In case of overdose, it is recommended that serum phosphorus levels, serum calcium levels and renal function be measured immediately and monitored periodically until resolution to normal/baseline levels. In case of hyperphosphatemia, withhold CRYSVITA and initiate appropriate medical treatment.
5.5 Withdrawal

Abrupt withdrawal of intrathecal baclofen, regardless of the cause, has resulted in sequelae that included high fever, altered mental status, exaggerated rebound spasticity and muscle rigidity that in rare cases progressed to rhabdomyolysis, multiple organ- system failure, and death. In the first 9 years of post-marketing experience, 27 cases of withdrawal temporally related to the cessation of baclofen therapy were reported; six patients died. In most cases, symptoms of withdrawal appeared within hours to a few days following interruption of baclofen therapy. Common reasons for abrupt interruption of intrathecal baclofen therapy included malfunction of the catheter (especially disconnection), low volume in the pump reservoir, and end of pump battery life; human error may have played a causal or contributing role in some cases. Cases of intrathecal mass at the tip of the implanted catheter leading to withdrawal symptoms have also been reported, most of them involving pharmacy compounded analgesic admixtures [see Warnings and Precautions (5.10)] . 

Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal.

All patients receiving intrathecal baclofen therapy are potentially at risk for withdrawal. Early symptoms of baclofen withdrawal may include return of baseline spasticity, pruritus, hypotension, and paresthesias. Some clinical characteristics of the advanced intrathecal baclofen withdrawal syndrome may resemble autonomic dysreflexia, infection (sepsis), malignant hyperthermia, neuroleptic-malignant syndrome, or other conditions associated with a hypermetabolic state or widespread rhabdomyolysis.

Rapid, accurate diagnosis and treatment in an emergency-room or intensive-care setting are important in order to prevent the potentially life-threatening central nervous system and systemic effects of intrathecal baclofen withdrawal. The suggested treatment for intrathecal baclofen withdrawal is the restoration of intrathecal baclofen at or near the same dosage as before therapy was interrupted. However, if restoration of intrathecal delivery is delayed, treatment with GABA-ergic agonist drugs such as oral or enteral baclofen, or oral, enteral, or intravenous benzodiazepines may prevent potentially fatal sequelae. Oral or enteral baclofen alone should not be relied upon to halt the progression of intrathecal baclofen withdrawal.

Seizures have been reported during overdose and with withdrawal from intrathecal baclofen as well as in patients maintained on therapeutic doses of intrathecal baclofen.
Necroptosis has been shown to contribute to myocardial ischemia reperfusion injury (MIRI). This study aims to gain new insights into the signaling pathway of necroptosis in rat MIRI using RNA sequencing. MIRI was induced in male rats by ligating the left anterior descending coronary artery for 30 min, followed by reperfusion for 120 min. RNA sequencing was performed to obtain mRNA profiles of MIRI group and MIRI group treated with necrostatin-1 (Nec-1,an inhibitor of necroptosis). Differentially expressed genes (DEGs) were then identified. The DEGs were prominently enriched in the TNF-α signaling pathway, the MAPK signaling pathway and cytokine-cytokine receptor pathways. The majority of the results were associated with genes like Thumpd3,Egr2,Dot1l,Cyp1a1,Dbnl,which primarily regulate inflammatory response and apoptosis, particularly in myocardium. The above results suggested that Nec-1 might be involved in the regulation of necroptosis and the inflammatory response through the above-mentioned genes.
Placebo on weeks one and two. Morphine 8 mg/day on week three.
Patients with coronary artery disease might benefit from successful percutaneous coronary intervention (PCI). However, there is currently no consensus on an optimal treatment modality for single lesions resulting in coronary total occlusion (CTO). Since the other coronary arteries are often lesion-free, or with stenosis of less than 50%, patients often present with no symptoms. Although the expert consensus on CTO lesion suggests reducing the incidence of long-term adverse events via successful revascularization, there are few retrospective studies on single CTO lesions. To date, it is unclear whether successful PCI based on optimal medication treatment (OMT) can increase myocardial viability and the extent of myocardial viability related to prognosis of those CTO patients. Therefore, the aim of this multi-center, prospective, open labeled, non-randomized controlled study was to determine if the improvement to myocardial viability in single CTO patients with successful PCI plus OMT was superior to that of patients with only OMT.
We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
Standard of care (SOC) plus a dose-escalation with 4 cohorts with 3-6 subjects/cohort who receive doses of 5, 10，15 and 20 ×10E7 cells. Proceed from lower dose to next higher dose if no safety concerns for each cohort.